

Date 10/12/2025
Your Ref
Our Ref 10831

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to endometrial cancer prescribing.

Question:

1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

Answer:

- Dostarlimab (Jemperli) - 6
- Dostarlimab (Jemperli) AND Chemotherapy - 6
- Hormone therapy (Progesterone or Letrozole) - 0
- Pembrolizumab (Keytruda) monotherapy - 8
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda) - 6
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 36
- Any other SACT - 0
- Any other Chemotherapy - 0
- Durvalumab with platinum-based chemotherapy - 0
- Pembrolizumab with platinum-based chemotherapy – 5<

Question:

2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

Answer:

- Dostarlimab (Jemperli) AND Chemotherapy - 6
- Durvalumab with platinum-based chemotherapy - 0
- Pembrolizumab with platinum-based chemotherapy - 0
- Hormone therapy (Progesterone or Letrozole) - 0
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 34

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

- Any other SACT - 0
- Any other chemotherapy – 5<

Question:

3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Answer:

Full Title	Recruited
TroFuse-033, A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)	5<

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive